Polypeptides to inhibit epstein barr viral protein BHRF1 and B cell lymphoma family proteins

Patent metadata

Field	Value
Publication number	US-9750814-B2
Application number	US-201615262716-A
Country	US
Kind code	B2
Filing date	Sep 12, 2016
Priority date	Mar 12, 2014
Publication date	Sep 5, 2017
Grant date	Sep 5, 2017

Abstract

The present invention provides designed polypeptides that selectively bind to and inhibit Epstein Barr protein BHFR1, and B cell lymphoma family proteins, and are thus useful for treating Epstein Barr-related diseases and cancer.

First claim

We claim:

1. A polypeptide comprising an amino acid sequence having at least 50% amino acid sequence identity over its length relative to the amino acid sequence of SEQ ID NO. 1, wherein the polypeptide selectively binds to a protein selected from the group consisting of Epstein Barr protein BHFR1, and B cell lymphoma family proteins selected from the group consisting of myeloid cell leukemia 1 (Mcl-1), B-cell lymphoma 2 (Bcl-2), Bcl-2-like protein 1 (BCL2L1/Bcl-XL), Bcl-2-like protein 10 (BCL2L10/Bcl-B), Bcl-2-like protein A1 (A1/Bfl-1), and Bcl-w.

2. The polypeptide of claim 1 , comprising an amino acid sequence having at least 66% identity over its length relative to the amino acid sequence of SEQ ID NO. 1.

3. The polypeptide of claim 1 , wherein the polypeptide comprises an amino acid sequence having at least 50% amino acid sequence identity over its length relative to the amino acid sequence selected from the group consisting of SEQ ID NOS:2-6 and 265.

4. The polypeptide of claim 3 , wherein the polypeptide comprises an amino acid sequence having at least 66% amino acid sequence identity over its length relative to the amino acid sequence selected from the group.

5. The polypeptide of claim 1 , wherein the polypeptide is selected from the group consisting of:
(a) a polypeptide that comprises an amino acid sequence according to SEQ ID NO: 7, wherein the polypeptide binds to BHFR1;
(b) a polypeptide that comprises an amino acid sequence according to SEQ ID NO: 8, wherein the polypeptide binds to Bcl-2;
(c) a polypeptide that comprises an amino acid sequence according to SEQ ID NO:9, wherein the polypeptide binds to binds to Bcl-2-like protein 1 (BCL2L1/Bcl-xL);
(d) a polypeptide that comprises an amino acid sequence according to SEQ ID NO: 10, wherein the polypeptide binds to Bcl-2-like protein 10 (BCL2L10/Bcl-B);
(e) a polypeptide that comprises an amino acid sequence according to SEQ ID NO: 11, wherein the polypeptide binds to Bcl-2-like protein A1 (A1/Bfl-1);
(f) a polypeptide that comprises an amino acid sequence according to SEQ ID NO: 12, wherein the polypeptide binds to Bcl-2-like protein Mcl-1;
(g) a polypeptide that comprises an amino acid sequence according to SEQ ID NO: 276, wherein the polypeptide binds to Bcl-2-like protein 2 (BCL2L2/Bcl-w).

6. The polypeptide of claim 1 , wherein the polypeptide comprises the amino acid sequence selected from the group consisting of SEQ ID NOS: 1-6 and 262-273.

7. The polypeptide of claim 1 , wherein the polypeptide comprises an amino acid sequence having at least 50% identity over its length relative to the amino acid sequence of SEQ ID NO:13.

8. The polypeptide of claim 7 , comprising at least one conservative substitution corresponding to residues 3, 13, 21, 28, 31, 33, 46, 48, 49, 61, 62, 65, 79, 84, 103, and 104 of the amino acid sequence of SEQ ID NO: 13.

9. The polypeptide of claim 8 , comprising the substitutions K31E, E48R, and E65R.

10. The polypeptide of claim 9 , further comprising the substitutions I21L, Q79L, L84Q, and H104R.

11. The polypeptide of claim 1 , further comprising a cell-penetrating peptide.

12. A pharmaceutical composition, comprising the polypeptide of claim 1 and a pharmaceutically acceptable carrier.

13. The pharmaceutical composition of claim 12 further comprising an antibody.

14. The pharmaceutical composition of claim 12 , wherein the carrier comprises a polymer.

15. The pharmaceutical composition of claim 14 , wherein the polymer comprises a hydrophilic block and an endosomolytic block.

16. The pharmaceutical composition of claim 15 , wherein the hydrophilic block comprises polyethylene glycol methacrylate, and wherein the endosomolytic block comprises a diethylaminoethyl methacrylate-butyl methacrylate copolymer.

17. The pharmaceutical composition of claim 14 , wherein the polymer is a stimuli-responsive polymer that responds to one or more stimuli selected from the group consisting of pH, temperature, UV-visible light, photo-irradiation, exposure to an electric field, ionic strength, and the concentration of certain chemicals by exhibiting a property change.

18. A recombinant nucleic acid encoding the polypeptide of claim 1 .

19. A recombinant expression vector comprising the nucleic acid of claim 18 operatively linked to a promoter.

20. A recombinant host cell comprising the recombinant expression vector of claim 19 .

21. A method of treating an Epstein-Barr virus-related disease comprising administering to a subject in need thereof a therapeutically effective amount of one or more of the polypeptide of claim 1 , or salts thereof, pharmaceutical compositions thereof, a recombinant nucleic acid encoding the one or more polypeptide, a recombinant expression vector comprising the recombinant nucleic acids, and/or a recombinant host cells comprising the recombinant expression vector, to treat and/or limit Epstein-Barr virus related diseases wherein the polypeptide or encoded polypeptide selectively inhibits BHRF 1.

22. A method for treating cancer, comprising administering to a subject in need thereof a therapeutically effective amount of one or more of the polypeptide of claim 1 , or salts thereof, to treat cancer, wherein the or encoded polypeptide selectively inhibits one or more of Mcl-1, Bcl-2, BCL2L1/Bcl-XL, BCL2L10/Bci-B, A1/Bfl-1, and Bci-w.

23. A method for determining the Bcl-2 phenotype of a tumor, comprising contacting tumor cells, tumor cell lysates or tumor cellular components with one or more polypeptides selected from the group consisting of SEQ ID NOS: 1-6, 8-12, 262-273 and 276, under conditions suitable to promote apoptosis signaling in cells of the tumor that express a bcl-2 homologue targeted by the one or more polypeptides; and determining BCL2 dependency of the tumor based on the polypeptide.

Assignees

• Univ Washington

Inventors

• Procko Erik
• Baker David
• Berguig Geoffrey Y
• Stayton Patrick S
• Song Yifan
• Berger Stephanie Ann
• Silva Daniel-Adriano

Classifications

• A61K38/1709 Primary

  from mammals · CPC title

• A61K47/32 Primary

  Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers {, poly(meth)acrylates, or polyvinyl pyrrolidone} · CPC title

• A61K35/17

  Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00) · CPC title

• C07K14/4748

  Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE · CPC title

• C07K14/4747

  Apoptosis related proteins · CPC title